Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. - Wikidata - wikimedia - TriplyDB

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

http://www.wikidata.org/entity/Q42575030

about

Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice Moving from basic toward systems pharmacodynamic models.Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Array of translational systems pharmacodynamic models of anti-cancer drugs.Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Manganese-Stimulated Kisspeptin Is Mediated by the IGF-1/Akt/Mammalian Target of Rapamycin Pathway in the Prepubertal Female Rat.Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.

P2860

Q34600979-4DEAE3E0-0DCD-46F9-A614-2DB499414DE2 Q37096317-68193366-C8C0-448F-B70C-7E972979FB96 Q37119137-8402057F-6A34-4D68-B1CD-35656689018D Q38666243-28FD5CA1-3A50-4EEF-831A-40600002A908 Q38757723-B8C4B524-794F-49F0-B86F-7EBEBA8DF98E Q38988505-495DFC57-ADCA-4052-AB13-A8058A3D2F42 Q39742601-6A4DD116-412A-41BD-898D-E59871AAB4DB Q40670954-49E561DD-6BE6-4D03-9FEA-7CD1C0D8734B Q42392474-D5F40E1F-ED3B-4224-9C25-F76D8F830C1B Q51615851-C14D0480-3B47-42F9-977D-9A3D9C7139C9

P2860

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

http://www.wikidata.org/entity/Q42575030

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@en

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@nl

type

label

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@en

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@nl

prefLabel

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@en

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@nl

P1433

Q42575030-F1D60415-36E2-40E0-B3F9-0DA8E7A21044

P1476

Q42575030-D1ADB350-66DF-4C0E-B2CD-0EFBC2AF62B6

P2093

Q42575030-16741236-BED3-42B8-AFA7-70D406484405

Q42575030-9995BAAB-4C30-4EB5-8563-DEEE4E9DF1A6

Q42575030-CB901CE1-05F3-4C8D-B28E-2D1C719AAFBE

Q42575030-D3040471-4520-49E3-BD4A-20D2B4351A66

Q42575030-EBD50641-A2CE-469A-B657-98CB75810803

Q42575030-EF977C9B-E73E-4681-B94C-634C737F204D

Q42575030-F5BE3649-9C85-44A3-9F19-443F05EE8B7E

P2860

Q42575030-023B9FDF-40B6-4E66-B605-10810FBAC863

Q42575030-0897DED5-2CEF-479A-BB2E-9038CE44961C

Q42575030-18ED2729-B265-4410-9DFD-CE2432CFB8B5

Q42575030-1D89B31B-8929-4C24-8EA8-CA9C79D23416

Q42575030-2143FA7E-F384-43F8-BE86-1B6EC256F936

Q42575030-244ECA0D-84DD-4278-BAC4-E464A8D675DF

Q42575030-26779B9F-CC19-4768-A225-F073F0A00762

Q42575030-317D8A5C-DA12-4D36-ACE6-4535A2A282E8

Q42575030-38E1E0D5-267D-45C3-A40A-8C39A132D41A

Q42575030-3BA96910-E1F7-47F0-BA19-D757EFB608EC

P2888

Q42575030-1350B7B9-68AF-4673-8F3F-3FB636595008

P304

Q42575030-41830812-AC99-4F5C-8D38-C08133AD93D5

P31

Q42575030-54EFE326-657B-48ED-A40D-EA06CF9AA676

P356

Q42575030-117B8DC4-0279-4722-A710-0C5A2075C4C0

P433

Q42575030-9A0E5F17-BB97-4679-9934-F57C72B0A2CC

P478

Q42575030-E754101E-D336-48E1-890B-97490D6CF6E2

P577

Q42575030-86AFF509-0551-4BED-90A5-E2DACC67B570

P6179

Q42575030-7F5A2B86-5519-458F-8D3D-F4673E834F02

P698

Q42575030-F0F35061-907B-4DB8-A20F-D2FF7074C4FF

P932

Q42575030-3ED1341C-DD80-46B5-B2C4-B754C85DB55D

P356

S00280-013-2116-Y

P1433

Cancer Chemotherapy and Pharmacology

P1476

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

@en

P2093

Bonnie H Hylander

http://www.w3.org/2001/XMLSchema#string

Dipti K Pawaskar

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Repasky

http://www.w3.org/2001/XMLSchema#string

Gerald J Fetterly

http://www.w3.org/2001/XMLSchema#string

Robert M Straubinger

http://www.w3.org/2001/XMLSchema#string

Wen W Ma

http://www.w3.org/2001/XMLSchema#string

William J Jusko

http://www.w3.org/2001/XMLSchema#string

P2860

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

BAY 43-9006: preclinical data.

Pharmacodynamic modeling of time-dependent transduction systems.

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.

Targeting mTOR for cancer treatment.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Sorafenib: in advanced renal cancer.

P2888

s00280-013-2116-y

P304

1219-1229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2116-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048575460

http://www.w3.org/2001/XMLSchema#string

P698

23455451

http://www.w3.org/2001/XMLSchema#string

P932

3755750

http://www.w3.org/2001/XMLSchema#string